FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses-Reference-Cited by-同舟云学术

FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses

Published:2010-02-01 Issue:2 Volume:88 Page:346-359
ISSN:0360-4012
Container-title:Journal of Neuroscience Research
language:en
Short-container-title:J. Neurosci. Res.

Author:

Papadopoulos Dimitrios,Rundle Jon,Patel Ryan,Marshall Ian,Stretton Jennifer,Eaton Rachel,Richardson Jill C.,Gonzalez Maria I.,Philpott Karen L.,Reynolds Richard

Publisher

Wiley

Subject

Cellular and Molecular Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jnr.22196/fullpdf

Reference60 articles.

1. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration;Allende;J Biol Chem,2004

2. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment;Antel;J Neuroimmunol,2006

3. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis;Balatoni;Brain Res Bull,2007

4. Axonal protection using flecainide in experimental autoimmune encephalomyelitis;Bechtold;Ann Neurol,2004

5. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation;Bitsch;Brain,2000

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Delimiting MOGAD as a disease entity using translational imaging;Frontiers in Neurology;2023-12-07

2. Roflumilast exerted neuroprotective effect in myelin oligodendrocyte glycoprotein35-55 (MOG35-55)-induced experimental autoimmune encephalitis (EAE) model;Journal of Research in Pharmacy;2023

3. Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions;MedComm;2022-08

4. A2B Adenosine Receptors and Sphingosine 1-Phosphate Signaling Cross-Talk in Oligodendrogliogenesis;Frontiers in Neuroscience;2021-05-26

5. Host sphingolipids: Perspective immune adjuvant for controlling SARS-CoV-2 infection for managing COVID-19 disease;Prostaglandins & Other Lipid Mediators;2021-02